Rescriptor (Delavirdine Mesylate) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 26, 2012

Rescriptor

Human Immunodeficiency Virus »

HIV facts

The human immunodeficiency virus (HIV) is a type of virus called a retrovirus, which infects humans when it comes in contact with tissues such as those that line the vagina, anal area, mouth, or eyes, or through a break in the skin.
HIV infection is generally a slowly progressive disease in which the virus is present throughout the body at all stages of the disease.
Three stages of HIV infection have been described.

The initial stage of infection (primary infection), which occurs within weeks of acquiring the virus, and often is characterized by a flu- or mono-like illness that generally resolves within weeks.
The stage of chronic asymptomatic infection (meaning a long duration of infection without symptoms) lasts an average of eight to 10 years.
The stage of symptomatic infection, in which the body's immune (or defense) system has...

Read the Human Immunodeficiency Virus article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Rescriptor User Reviews >>

Rescriptor

HIV AIDS Myths and Facts Slideshow Pictures

Take the HIV/AIDS Quiz

AIDS Retrospective Slideshow Pictures

font size

RESCRIPTOR®
(delavirdine mesylate) Tablets

DRUG DESCRIPTION

RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor of the human immuno deficiency virus type 1 (HIV-1). The chemical name of delavirdine mesylate is piperazine, 1-[3-[(1-methyl-ethyl) amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl) amino]-1H-indol-2-yl]carbonyl]-,monomethane sulfonate. Its molecular formula is C₂₂H₂₈N₆O₃S•E CH₄O₃S, and itsmolecular weight is 552.68. The structural formula is:

RESCRIPTOR (delavirdine mesylate) Structural Formula Illustration

Delavirdine mesylate is an odorless white-to-tan crystalline powder. The aqueous solubility of delavirdine free base at 23° C is 2942 µg/mL at pH 1.0, 295 µg/mL at pH2.0, and 0.81 µg/mL at pH 7.4.

Each RESCRIPTOR (delavirdine mesylate) Tablet, for oral administration, contains 100 or 200 mg of delavirdine mesylate (hence forth referred to as delavirdine). Inactive ingredients consistof lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and carnauba wax. In addition, the 100 mg tablet contains Opadry White YS-1-7000-E and the 200 mg tablet contains hypromellose, Opadry White YS-1-18202-A and Pharmaceutical Ink Black.

What are the possible side effects of delavirdine (Rescriptor)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
easy bruising or bleeding, unusual weakness;
fever, chills, body aches, flu symptoms; or
any other signs of new infection.

Less serious side effects may...

Read All Potential Side Effects and See Pictures of Rescriptor »

What are the precautions when taking delavirdine mesylate (Rescriptor)?

Before taking delavirdine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver problems.

To decrease your risk of spreading HIV disease to others, always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity. Consult your doctor or pharmacist for more details.

During pregnancy, this medication should be used only when clearly needed. However, HIV medicines are now usually given to pregnant women with HIV. Treatment has been shown to...

Read All Potential Precautions of Rescriptor »

Last reviewed on RxList: 11/25/2008
This monograph has been modified to include the generic and brand name in many instances.